Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of LodienT vs Twynsta in Healthy Volunteers
NCT04667624Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lodient in hypertension (HTN) (2 arms), sponsored by Hanlim Pharm. Primary endpoints: Area Under the Concentration-Time Curve from time zero to last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Feb 2020; status: completed.
02
Drugs
Lodient
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04667624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667624.